A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma

about

A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma

Item

http://www.wikidata.org/entity/Q58699971

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma

@en

A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma

@nl

type

Item

label

A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma

@en

A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma

@nl

prefLabel

A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma

@en

A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma

@nl

P1476

A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma

@en

P2093

Kamleshun Ramphul

http://www.w3.org/2001/XMLSchema#string

Petras Lohana

http://www.w3.org/2001/XMLSchema#string

Ruhi Sonaye

http://www.w3.org/2001/XMLSchema#string

Shaheen Sombans

http://www.w3.org/2001/XMLSchema#string

Stephanie G Mejias

http://www.w3.org/2001/XMLSchema#string

Vivian C Agumadu

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-5 and IL-5 receptor in health and diseases

Eosinophilic Inflammation in Asthma

Reslizumab for Poorly Controlled, Eosinophilic Asthma

Advances in the immunobiology of eosinophils and their role in disease.

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics.

Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab.

Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.

Eosinophil trafficking in allergy and asthma.

P304

e3216

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7759/CUREUS.3216

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30416896

http://www.w3.org/2001/XMLSchema#string

P921

interleukin

asthma

P932

6223665

http://www.w3.org/2001/XMLSchema#string